MaltSci 麦伴科研

Appearance

Popular Reports / nephrology

This report is written by MaltSci based on the latest literature and research findings

What are the mechanisms of acute kidney injury? ​

Abstract ​

Acute kidney injury (AKI) is a critical clinical syndrome characterized by a rapid decline in renal function, leading to the accumulation of waste products and disturbances in fluid and electrolyte balance. The global prevalence of AKI has increased significantly, particularly in hospitalized patients, where it is associated with high morbidity and mortality rates. Understanding the multifactorial mechanisms underlying AKI is essential for developing effective prevention and treatment strategies. This review systematically explores the pathophysiological mechanisms of AKI, organized into three primary categories: pre-renal, intrinsic renal, and post-renal factors. Pre-renal factors involve hemodynamic alterations that compromise renal perfusion, while intrinsic renal factors are characterized by direct damage to renal parenchyma, often due to nephrotoxins or ischemia. Post-renal causes relate to obstructive processes that impede urinary flow. The interplay between these mechanisms is complex, with systemic and local inflammatory responses playing critical roles in the progression of AKI. Additionally, we discuss hemodynamic changes impacting renal blood flow, cellular and molecular injury mechanisms, and the role of oxidative stress and inflammation in AKI. Traditional and novel biomarkers for early detection of AKI are explored, emphasizing their clinical implications. Finally, we highlight future directions in AKI research, focusing on potential therapeutic targets and advancements in biomarker development. Understanding these mechanisms not only enhances our knowledge of AKI but also informs the development of targeted therapies that may mitigate its devastating consequences.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Pathophysiological Mechanisms of Acute Kidney Injury
    • 2.1 Pre-renal Factors
    • 2.2 Intrinsic Renal Factors
    • 2.3 Post-renal Factors
  • 3 Hemodynamic Changes in AKI
    • 3.1 Renal Blood Flow and Filtration
    • 3.2 Impact of Systemic Circulation
  • 4 Cellular and Molecular Injury Mechanisms
    • 4.1 Apoptosis and Necrosis
    • 4.2 Role of Oxidative Stress
    • 4.3 Inflammatory Pathways
  • 5 Biomarkers for Early Detection of AKI
    • 5.1 Traditional Biomarkers
    • 5.2 Novel Biomarkers and Their Clinical Implications
  • 6 Future Directions in AKI Research
    • 6.1 Therapeutic Targets
    • 6.2 Advances in Biomarker Development
  • 7 Summary

1 Introduction ​

Acute kidney injury (AKI) is a critical clinical syndrome characterized by a rapid decline in renal function, leading to the accumulation of waste products and disturbances in fluid and electrolyte balance. The global prevalence of AKI has increased significantly, particularly in hospitalized patients, where it is associated with high morbidity and mortality rates. Despite advances in medical care, the incidence of AKI remains a major challenge in both acute and chronic settings, often serving as a precursor to chronic kidney disease (CKD) and end-stage renal disease (ESRD) [1][2]. Understanding the multifactorial mechanisms underlying AKI is essential for developing effective prevention and treatment strategies.

The significance of investigating the pathophysiological mechanisms of AKI lies not only in the immediate clinical implications but also in the long-term consequences for renal health. AKI can result from various etiological factors, including ischemic injury, nephrotoxicity, and inflammatory processes [3][4]. These insults can trigger a cascade of cellular and molecular events that lead to tubular cell injury, endothelial dysfunction, and systemic inflammatory responses [5][6]. The interplay between these mechanisms can determine the severity of kidney injury and the potential for recovery, highlighting the importance of elucidating these pathways to inform clinical practice [6][7].

Current research has identified three primary categories of AKI mechanisms: pre-renal, intrinsic renal, and post-renal factors. Pre-renal causes typically involve hemodynamic alterations that compromise renal perfusion, while intrinsic renal factors are characterized by direct damage to renal parenchyma, often due to nephrotoxins or ischemia. Post-renal causes are related to obstructive processes that impede urinary flow [6][8]. The interactions among these factors are complex, with systemic and local inflammatory responses playing critical roles in the progression of AKI [4][7].

In this review, we will systematically explore the pathophysiological mechanisms of AKI, organized as follows:

  1. Pathophysiological Mechanisms of Acute Kidney Injury: This section will delve into the various pre-renal, intrinsic, and post-renal factors contributing to AKI. We will examine the cellular and molecular responses to these insults, including the roles of apoptosis, necrosis, and oxidative stress [5][9].

  2. Hemodynamic Changes in AKI: Here, we will discuss how alterations in renal blood flow and systemic circulation impact kidney function during AKI [6][8].

  3. Cellular and Molecular Injury Mechanisms: This section will focus on the intricate cellular processes involved in AKI, including apoptosis, necrosis, and the activation of inflammatory pathways, with particular emphasis on the role of immune cells in the pathogenesis of AKI [4][7].

  4. Biomarkers for Early Detection of AKI: We will explore traditional and novel biomarkers that can aid in the early diagnosis of AKI, as well as their implications for clinical practice [4][10].

  5. Future Directions in AKI Research: This section will highlight potential therapeutic targets and advancements in biomarker development that could improve outcomes for patients with AKI [2][9].

By synthesizing current research findings, this review aims to provide a comprehensive overview of the mechanisms of AKI, ultimately contributing to improved management approaches for this prevalent condition. Understanding these mechanisms not only enhances our knowledge of AKI but also informs the development of targeted therapies that may mitigate its devastating consequences.

2 Pathophysiological Mechanisms of Acute Kidney Injury ​

2.1 Pre-renal Factors ​

Acute kidney injury (AKI) is characterized by a rapid decline in renal function, and its pathophysiology is complex, involving multiple mechanisms. The primary factors contributing to AKI can be broadly categorized into three main processes: hemodynamic changes, inflammatory reactions, and nephrotoxicity.

Pre-renal factors primarily refer to conditions that lead to a reduction in renal perfusion, resulting in decreased glomerular filtration rate (GFR). This can occur due to various causes, including hypovolemia from dehydration, hemorrhage, or excessive fluid loss. Hemodynamic changes are critical in the pathogenesis of AKI, as they can lead to renal ischemia, which, if prolonged, may result in intrinsic kidney injury. The renal vasculature is particularly sensitive to fluctuations in blood flow and pressure; thus, any significant alterations can precipitate AKI.

In addition to hemodynamic factors, inflammatory responses play a crucial role in the development of AKI. These responses can be initiated by ischemic events or nephrotoxic agents, leading to the activation of immune pathways that exacerbate renal injury. The involvement of tubular cells and various immune cell subtypes is significant in this context, as they contribute to the inflammatory milieu that further damages renal tissue. Inflammatory cytokines and chemokines released during this process can lead to tubular cell apoptosis and further impair renal function [4].

Nephrotoxicity, another critical mechanism, can arise from exposure to various nephrotoxic agents, including certain medications, contrast dyes, and endogenous toxins such as myoglobin in rhabdomyolysis. The presence of these agents can lead to direct damage to renal tubular cells, compounding the injury initiated by pre-renal factors and inflammation [11].

The interactions between these mechanisms are intricate; for instance, the development of one factor often instigates another, thereby complicating the clinical presentation of AKI. The interplay between hemodynamic changes, inflammation, and nephrotoxicity can significantly influence the severity and duration of AKI, ultimately affecting patient outcomes [6].

Understanding these mechanisms is vital for the prevention and management of AKI, particularly in critically ill patients, where the risk of developing AKI is heightened. Effective strategies include optimizing hemodynamics, avoiding nephrotoxic agents, and implementing early interventions based on the identification of risk factors [12]. By recognizing the pre-renal factors and their contributions to the overall pathophysiology of AKI, healthcare providers can better tailor interventions to mitigate the impact of this syndrome on patient health.

2.2 Intrinsic Renal Factors ​

Acute kidney injury (AKI) is characterized by a rapid decline in kidney function and can result from various intrinsic renal factors. The pathophysiology of AKI is complex and involves multiple overlapping mechanisms that can be categorized primarily into three main processes: hemodynamic changes, inflammatory reactions, and nephrotoxicity. Each of these processes contributes to the development and progression of AKI, and they often interact with one another, complicating the overall pathophysiological landscape.

Hemodynamic changes refer to alterations in renal blood flow and glomerular filtration pressure. These changes can lead to ischemia, which is a critical factor in the pathogenesis of AKI. For instance, in cases of trauma or hemorrhagic shock, reduced perfusion pressure can result in acute tubular injury, particularly in the proximal tubules, which are highly sensitive to ischemic conditions due to their high metabolic demands[11].

Inflammatory reactions are another significant contributor to AKI. Cells of the innate immune system, such as granulocytes and macrophages, play a pivotal role in mediating renal injury through the secretion of pro-inflammatory mediators like cytokines and chemokines. This inflammatory response can exacerbate kidney damage by promoting further tubular injury and disrupting the renal microenvironment. Inflammatory cascades, including oxidative stress and immune thrombosis, are involved in mediating these injuries and can lead to maladaptive repair mechanisms, further complicating recovery from AKI[13].

Nephrotoxicity, which can arise from exposure to nephrotoxic agents such as certain medications or contrast agents, is also a crucial factor in the development of AKI. These agents can directly damage renal tubular cells, leading to cell death and impairing renal function. The cumulative effects of these nephrotoxic insults can lead to a condition where the kidney's ability to repair itself is compromised, thus increasing the risk of progressing to chronic kidney disease (CKD) or end-stage renal disease[14].

Additionally, the interplay between these mechanisms is significant. For example, the activation of inflammatory pathways can lead to further hemodynamic instability and exacerbate nephrotoxic effects. The intricate relationship between tubular injury, inflammation, and hemodynamic changes highlights the multifactorial nature of AKI[6].

In summary, the mechanisms underlying AKI involve a combination of hemodynamic changes, inflammatory responses, and nephrotoxic effects, each contributing to the overall pathology. Understanding these mechanisms is crucial for developing effective therapeutic strategies to mitigate the impacts of AKI and prevent its progression to chronic kidney disease.

2.3 Post-renal Factors ​

The knowledge base information is insufficient. Please consider switching to a different knowledge base or supplementing relevant literature.

3 Hemodynamic Changes in AKI ​

3.1 Renal Blood Flow and Filtration ​

Acute kidney injury (AKI) is characterized by a rapid decline in kidney function, which can arise from various underlying mechanisms. One significant aspect of AKI is related to hemodynamic changes, particularly alterations in renal blood flow and glomerular filtration rate (GFR).

Hemodynamic changes in AKI can manifest as reductions in renal blood flow, which may be influenced by multiple factors including systemic hypotension, sepsis, and nephrotoxic agents. These conditions can lead to a decrease in perfusion pressure, ultimately impairing the kidney's ability to filter blood effectively. In particular, septic acute kidney injury has been noted to account for nearly 50% of AKI cases in intensive care settings, affecting 15% to 20% of ICU patients. This form of AKI may involve complex interactions where hyperdynamic circulation could contribute to a unique variant termed hyperemic acute renal failure, indicating that renal ischemia may not be the sole mechanism at play (Wan et al. 2008) [15].

The interplay between ischemia and inflammation is also crucial in understanding renal blood flow dynamics. Inflammatory processes can exacerbate renal injury by affecting the microcirculation within the kidney. In cases of ischemic injury, the initial reduction in blood flow can lead to a cascade of inflammatory responses, which further compromises renal function and may contribute to intrarenal hypoperfusion (Glodowski & Wagener 2015) [16].

Moreover, the phenomenon of "no-reflow" is a critical concept in the context of renal ischemia. This refers to the sustained reduction in renal blood flow that persists even after the initial cause of ischemia has been resolved. Research has indicated that pericytes, which are contractile cells associated with capillaries, play a significant role in this process. Following ischemia, pericytes can constrict renal capillaries, leading to blockages that exacerbate kidney injury. Targeting the contractility of pericytes has been suggested as a potential therapeutic approach to mitigate the impact of AKI (Freitas & Attwell 2022) [17].

The complex interactions among hemodynamic changes, inflammatory responses, and cellular mechanisms highlight the multifaceted nature of AKI. As a result, the clinical presentation and progression of AKI can vary widely depending on the severity and duration of these insults, as well as the underlying health status of the patient (Juncos et al. 2022) [6]. Understanding these mechanisms is essential for developing targeted interventions aimed at preventing and treating AKI effectively.

3.2 Impact of Systemic Circulation ​

Acute kidney injury (AKI) is characterized by a rapid decline in kidney function, often leading to significant morbidity and mortality. The mechanisms underlying AKI are multifaceted, with hemodynamic changes playing a critical role. Hemodynamic alterations can lead to impaired renal perfusion, which is a primary factor contributing to the development of AKI.

One of the central aspects of AKI is the reduction of renal blood flow, which can result from various factors including systemic circulation changes. The kidneys are particularly susceptible to ischemia due to their unique microcirculatory anatomy, where the peritubular capillary network surrounds the renal tubules. This anatomical arrangement means that any reduction in renal perfusion can lead to substantial injury to tubular epithelial cells, which are highly dependent on adequate blood flow for oxygen and nutrient delivery. Studies have shown that in conditions of ischemia, such as during septic shock, the renal blood flow may be compromised, contributing to the pathophysiology of AKI [8].

Moreover, the interplay between systemic circulation and renal hemodynamics is complex. For instance, in septic acute kidney injury, nearly 50% of all AKI cases in intensive care settings are attributed to sepsis. It has been suggested that septic AKI may represent a unique form of acute renal failure characterized by hyperemia rather than ischemia, particularly in patients exhibiting hyperdynamic circulation. This indicates that while systemic circulation can lead to renal hypoperfusion, it can also create conditions of excessive blood flow that might paradoxically contribute to kidney injury through mechanisms such as inflammation and endothelial dysfunction [15].

The systemic consequences of AKI further complicate the hemodynamic landscape. AKI is associated with a systemic inflammatory response, leading to the release of cytokines and other inflammatory mediators that can affect not only the kidneys but also other organ systems. The activation of these systemic pathways can result in increased vascular permeability and tissue edema, exacerbating the injury [18]. The inflammatory response, coupled with the renal hypoperfusion, creates a vicious cycle that can lead to the progression of kidney injury and potential transition to chronic kidney disease [19].

In conclusion, the mechanisms of AKI, particularly regarding hemodynamic changes, highlight the critical impact of systemic circulation on renal function. The interplay of reduced renal perfusion, systemic inflammatory responses, and the unique anatomical features of renal microcirculation collectively contribute to the pathophysiology of AKI, emphasizing the need for a nuanced understanding of these interactions in developing therapeutic strategies.

4 Cellular and Molecular Injury Mechanisms ​

4.1 Apoptosis and Necrosis ​

Acute kidney injury (AKI) is characterized by a rapid decline in kidney function, leading to significant morbidity and mortality. The mechanisms underlying AKI are multifactorial and involve complex cellular and molecular injury processes, particularly apoptosis and necrosis, which play crucial roles in the pathophysiology of this condition.

Apoptosis, a form of programmed cell death, has been shown to be a significant contributor to AKI. Proximal tubule epithelial cells are particularly susceptible to apoptosis, and injury to these cells can severely impair renal function. During apoptosis, a series of well-coordinated events occur, primarily involving mitochondrial pathways that integrate various life and death signals. The BCL2 protein family is central to this process, where outer mitochondrial membrane injury leads to the release of pro-apoptotic factors that ultimately trigger cell death. This apoptotic process is not only limited to the renal tissue but can also have systemic effects, as factors released from the injured kidney may induce apoptosis and inflammation in distant organs, thereby contributing to the high morbidity associated with AKI (Havasi and Borkan, 2011) [20].

Necrosis, particularly regulated necrosis known as necroptosis, also plays a critical role in AKI. Unlike apoptosis, necroptosis results in the release of cellular contents and pro-inflammatory cytokines, which can instigate an inflammatory response in neighboring tissues. This necroinflammatory environment exacerbates tissue injury and can lead to lasting organ dysfunction. Recent studies have highlighted the significance of necroptosis in the context of acute tubular necrosis and nephron loss, suggesting that it may initiate a cascade of cell death that further propagates injury (Kolbrink et al., 2023) [21].

The interplay between apoptosis and necroptosis, along with other forms of cell death such as ferroptosis, adds complexity to the mechanisms of AKI. Ferroptosis, an iron-dependent form of non-apoptotic cell death characterized by lipid peroxidation, has emerged as a significant contributor to the pathogenesis of AKI. The accumulation of reactive oxygen species (ROS) and subsequent lipid peroxidation are central to this process, highlighting the role of oxidative stress in renal injury (Feng et al., 2022) [22].

In addition to these cellular death pathways, the inflammatory response is a critical aspect of AKI. The initiation and progression of kidney injury are closely linked to the activation of inflammatory pathways involving various immune cells, cytokines, and chemokines. This inflammatory milieu not only contributes to the acute injury but also influences the recovery phase, where the resolution of inflammation is essential for renal repair (Hu et al., 2017) [4].

In summary, the mechanisms of acute kidney injury are multifaceted, involving a combination of apoptosis, necroptosis, and ferroptosis, along with significant inflammatory responses. Understanding these pathways is crucial for developing therapeutic strategies aimed at mitigating kidney injury and enhancing recovery.

4.2 Role of Oxidative Stress ​

Acute kidney injury (AKI) is characterized by a rapid decline in renal function, and its pathophysiology is complex, involving various cellular and molecular injury mechanisms. A significant contributor to AKI is oxidative stress, which arises from an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses.

Oxidative stress plays a pivotal role in the development and progression of AKI. Reactive oxygen species, which include superoxide anions, hydrogen peroxide, and hydroxyl radicals, can cause cellular damage by inducing lipid peroxidation, protein oxidation, and DNA damage. This cellular injury can lead to apoptosis or necrosis of renal tubular cells, contributing to the overall decline in kidney function (Ratliff et al. 2016) [23].

The sources of ROS in AKI are multifactorial. Mitochondrial dysfunction is a primary source, as damaged mitochondria can produce excessive ROS, exacerbating oxidative stress (Ho & Shirakawa 2022) [24]. Other contributors include the activation of NADPH oxidase and inducible nitric oxide synthase, which further enhance ROS generation during kidney injury (Ratliff et al. 2016) [23]. Inflammatory processes also play a critical role, as the recruitment of immune cells and the release of pro-inflammatory cytokines can stimulate ROS production, creating a vicious cycle of injury (Nezu et al. 2017) [25].

In the context of drug-induced kidney injury, oxidative stress is a common mechanism. Many nephrotoxic drugs lead to the activation of inflammatory responses and subsequent oxidative damage to renal tubular cells. For instance, acute tubular necrosis (ATN), a common form of drug-induced AKI, is associated with oxidative stress-mediated injury that results from the activation of inflammatory pathways and the release of cytokines (Hosohata 2016) [26].

Furthermore, the interplay between oxidative stress and autophagy is crucial in AKI. Autophagy is a cellular process that removes damaged organelles and proteins, and its dysregulation can exacerbate oxidative stress. Both oxidative stress and autophagy are interconnected in their roles in kidney health and disease, indicating that enhancing autophagic processes may mitigate oxidative damage and improve renal outcomes (Sureshbabu et al. 2015) [27].

The potential for therapeutic interventions targeting oxidative stress in AKI is gaining attention. Antioxidants, such as resveratrol, have shown promise in preclinical studies by reducing oxidative stress and improving renal function (Rashid et al. 2023) [28]. Additionally, recent advances in nanotechnology have led to the development of antioxidant nanozymes that can effectively scavenge ROS, providing a novel approach to managing oxidative stress in kidney injury (Wu et al. 2023) [29].

In summary, oxidative stress is a central mechanism in the pathophysiology of acute kidney injury, contributing to cellular damage through various pathways, including mitochondrial dysfunction, inflammation, and dysregulation of autophagy. Understanding these mechanisms opens avenues for therapeutic strategies aimed at reducing oxidative stress and protecting renal function.

4.3 Inflammatory Pathways ​

Acute kidney injury (AKI) is characterized by a rapid decline in kidney function, often associated with high morbidity and mortality. The mechanisms underlying AKI are complex and multifactorial, involving a range of cellular and molecular injury mechanisms, particularly inflammatory pathways.

One of the central mechanisms of AKI involves the activation of inflammatory pathways. Inflammatory responses play a critical role in the initiation and progression of AKI, especially under ischemic conditions. Tubular cells and distinct immune cell subgroups are pivotal in the pathogenesis of inflammation associated with AKI. The infiltration of immune cells into the renal interstitium leads to the release of pro-inflammatory mediators, including cytokines and chemokines, which exacerbate tubular cell injury and death [4].

The inflammatory response in AKI can be triggered by various insults, such as ischemia, sepsis, or nephrotoxic agents. These insults initiate a cascade of events resulting in impaired microcirculation and activation of inflammatory pathways. This cascade often leads to tubular cell injury or death, further perpetuating the inflammatory cycle [1].

The interplay between different cell types, including macrophages, neutrophils, and renal tubular cells, is crucial in mediating the inflammatory response. For instance, macrophages can both induce injury through the secretion of inflammatory mediators and contribute to repair processes following injury. This dual role complicates the therapeutic approach to AKI, as targeting inflammation must be carefully balanced to avoid impairing the repair processes [13].

Reactive oxygen species (ROS) also play a significant role in the inflammatory response during AKI. They are generated in excess during renal injury and contribute to oxidative stress, which further damages renal cells and promotes inflammation [30]. The presence of ROS can activate various signaling pathways that lead to cell death, including apoptosis and necrosis, while also promoting the activation of pro-inflammatory pathways [3].

Furthermore, the cellular response to injury involves the activation of cell cycle pathways. During AKI, tubular cells can undergo cell cycle arrest, which is a protective mechanism in response to injury. However, prolonged cell cycle arrest can lead to cellular senescence, contributing to maladaptive repair and progression to chronic kidney disease [19].

The complexity of these interactions emphasizes the need for a deeper understanding of the inflammatory pathways involved in AKI. Recent advancements in research have highlighted the potential for targeted therapies that can modulate these inflammatory responses to enhance kidney repair and prevent progression to chronic kidney disease [31]. Understanding these mechanisms is critical for developing effective interventions to mitigate the effects of AKI and improve patient outcomes.

5 Biomarkers for Early Detection of AKI ​

5.1 Traditional Biomarkers ​

Acute kidney injury (AKI) is a multifactorial syndrome characterized by a sudden decline in kidney function, which can lead to significant morbidity and mortality. The mechanisms underlying AKI are diverse and can be categorized into several etiological groups, including prerenal, intrinsic renal, and postrenal causes.

Prerenal AKI typically results from factors that reduce renal blood flow, such as dehydration, heart failure, or systemic vasodilation. This reduction in perfusion can lead to ischemic injury to the renal tubules if not promptly addressed. Intrinsic renal AKI occurs due to direct damage to the kidney parenchyma, often resulting from nephrotoxic agents, infections, or ischemia. Common intrinsic causes include acute tubular necrosis (ATN), glomerulonephritis, and acute interstitial nephritis. Postrenal AKI is associated with obstruction of urinary outflow, which can occur due to conditions such as kidney stones, tumors, or enlarged prostates.

Traditional biomarkers for the diagnosis of AKI primarily include serum creatinine and urine output. However, these biomarkers have significant limitations. Serum creatinine levels are often delayed in reflecting true renal function changes and can be influenced by various factors such as muscle mass, age, and hydration status. Similarly, urine output is a nonspecific measure that may not adequately capture early renal impairment.

Recent advances have highlighted the need for novel biomarkers that can provide more timely and accurate detection of AKI. These biomarkers include Cystatin C, Neutrophil gelatinase-associated lipocalin (NGAL), Interleukin-18 (IL-18), and Kidney injury molecule-1 (KIM-1). Cystatin C is sensitive to early changes in kidney function, while NGAL is expressed soon after renal injury and can predict AKI post-kidney transplant and during cardiopulmonary bypass. IL-18 has been noted for its early detection in various contexts, including sepsis, and KIM-1 is upregulated following ischemic or toxic injury, offering prognostic value regarding the need for renal replacement therapy and mortality risk [32][33][34].

In summary, the mechanisms of AKI are complex and can arise from various prerenal, intrinsic, and postrenal factors. Traditional biomarkers such as serum creatinine and urine output have limitations that hinder early diagnosis. The development of novel biomarkers presents a promising avenue for improving early detection, prognostication, and subsequent management of AKI.

5.2 Novel Biomarkers and Their Clinical Implications ​

Acute kidney injury (AKI) is a multifactorial syndrome characterized by a rapid decline in renal function, and its pathophysiological mechanisms involve a complex interplay of cellular, molecular, metabolic, and immunologic factors. The understanding of these mechanisms is crucial for the identification of novel biomarkers that can facilitate early detection and improve clinical outcomes.

The traditional diagnostic criteria for AKI primarily rely on serum creatinine levels and urine output. However, these parameters have significant limitations, as they do not reflect real-time changes in kidney function or actual kidney injury. Specifically, serum creatinine can be a delayed indicator of renal impairment, often reflecting damage only after substantial nephron loss has occurred [35]. Consequently, there is a pressing need for more sensitive and specific biomarkers that can detect kidney injury earlier and provide insights into the underlying pathophysiological processes.

Recent advancements have identified several novel biomarkers that exhibit promise for early detection of AKI. These include:

  1. Cystatin C: This biomarker is sensitive to early and mild changes in kidney function and can detect renal impairment sooner than traditional markers [32].

  2. Neutrophil Gelatinase-Associated Lipocalin (NGAL): Expressed early after kidney injury, NGAL has shown potential in predicting AKI in various clinical scenarios, including post-kidney transplant and after cardiopulmonary bypass [32].

  3. Kidney Injury Molecule-1 (KIM-1): This biomarker is upregulated following ischemic or toxic injury and can predict the need for renal replacement therapy and mortality [32].

  4. Interleukin-18 (IL-18): This cytokine has been detected early in the context of AKI following kidney transplant, cardiopulmonary bypass, and sepsis, highlighting its potential as an early indicator of renal stress [32].

  5. L-FABP, IGFBP7, TIMP-2, and Clusterin: These markers have been associated with tubular damage and stress responses, and their roles in the detection and classification of AKI are under active investigation [35].

The clinical implications of these novel biomarkers are substantial. They not only enhance the ability to diagnose AKI earlier but also improve the understanding of the underlying mechanisms of kidney injury. This can lead to better prognostication, risk stratification, and targeted therapeutic interventions. For instance, the integration of these biomarkers into clinical practice can help differentiate between various forms of AKI, such as acute tubular necrosis and prerenal azotemia, thereby guiding appropriate management strategies [33].

Moreover, the use of biomarkers can significantly impact the design of clinical trials, providing valuable endpoints for evaluating therapeutic interventions aimed at preventing or reversing AKI. This shift towards precision medicine underscores the importance of identifying specific biomarkers that correlate with distinct pathophysiological processes, enabling tailored treatment approaches that improve patient care and outcomes [33].

In summary, the mechanisms of AKI are complex and multifaceted, necessitating a shift from traditional diagnostic approaches to the incorporation of novel biomarkers that provide deeper insights into kidney injury and its progression. The continued exploration of these biomarkers holds promise for revolutionizing the management of AKI and enhancing patient outcomes in various clinical settings.

6 Future Directions in AKI Research ​

6.1 Therapeutic Targets ​

Acute kidney injury (AKI) is characterized by a rapid decline in kidney function, which can result from various etiologies, including ischemia, nephrotoxic agents, and inflammatory responses. The pathophysiological mechanisms underlying AKI are complex and multifactorial, involving cellular, molecular, and immunological interactions.

Key mechanisms contributing to AKI include:

  1. Tubular Cell Injury and Death: The injury primarily affects renal tubular epithelial cells, leading to cell death through apoptosis and necrosis. This process is exacerbated by oxidative stress, inflammation, and alterations in mitochondrial function, which are pivotal in the progression of AKI [5].

  2. Inflammatory Responses: Inflammation plays a crucial role in the initiation and progression of AKI. The activation of innate and adaptive immune responses results in the recruitment of various immune cells to the site of injury, which further exacerbates tubular damage. Inflammatory cytokines and chemokines contribute to this process, indicating that modulation of inflammatory pathways may serve as a therapeutic target [4].

  3. Oxidative Stress: Increased production of reactive oxygen species (ROS) is a hallmark of AKI. ROS can damage cellular components, leading to further cell injury and death. The interplay between oxidative stress and mitochondrial dysfunction is particularly critical in the context of AKI [36].

  4. Ischemic Injury: Ischemia-reperfusion injury is a common cause of AKI, where the restoration of blood flow after a period of ischemia leads to an exacerbation of tissue damage due to inflammation and oxidative stress [3].

  5. Epigenetic Alterations: Recent studies have highlighted the role of epigenetic changes, such as DNA methylation and histone modifications, in the transition from AKI to chronic kidney disease (CKD). These alterations may serve as a "memory" of the initial injury, influencing the long-term outcome of kidney function [37].

Future directions in AKI research focus on understanding these mechanisms in greater depth and identifying novel therapeutic targets. Potential areas of investigation include:

  • Biological Therapies: Emerging strategies such as antibody therapy, cell therapy, and RNA therapy are being explored to mitigate AKI. These therapies aim to enhance renal repair processes and reduce inflammation and oxidative stress [38].

  • Targeting Inflammatory Pathways: Given the significant role of inflammation in AKI, therapies aimed at modulating the immune response may provide beneficial effects. This includes the development of biomarkers that can help identify patients at risk of AKI and guide therapeutic interventions [39].

  • Sirtuins and Metabolic Pathways: The role of sirtuins in regulating cellular metabolism and stress responses is gaining attention. Understanding how these proteins interact with other cellular mechanisms could lead to novel therapeutic strategies [5].

  • Translational Research: Integrating advanced technologies such as omics, imaging, and artificial intelligence into AKI research can facilitate the identification of new biomarkers and therapeutic targets, ultimately improving patient care [31].

In summary, the mechanisms of AKI involve a complex interplay of cellular injury, inflammation, oxidative stress, and metabolic dysregulation. Future research aims to unravel these mechanisms further and develop targeted therapies that can effectively prevent and treat AKI, as well as mitigate its progression to chronic kidney disease.

6.2 Advances in Biomarker Development ​

Acute kidney injury (AKI) is a complex syndrome characterized by a rapid decline in renal function, which can lead to significant morbidity and mortality. The mechanisms underlying AKI are multifaceted and can be categorized into several primary processes, including hemodynamic changes, inflammatory responses, and nephrotoxicity.

One of the central mechanisms involves hemodynamic changes, which can lead to reduced renal perfusion and oxygen delivery to the kidneys. This is often exacerbated by conditions such as sepsis or hypovolemia, resulting in ischemia and subsequent tubular cell injury. The interplay between hemodynamic factors and inflammatory responses is critical, as inflammatory cytokines and chemokines can further exacerbate renal injury by promoting vasoconstriction and increasing vascular permeability [6].

Inflammation plays a pivotal role in the pathophysiology of AKI. Both innate and adaptive immune responses are activated during renal injury, with immune cells such as neutrophils, macrophages, and dendritic cells contributing to tissue damage. For instance, dendritic cells are shown to orchestrate immune responses that can either promote tissue repair or contribute to further damage, highlighting their dual role in AKI [40]. Inflammatory cytokines released during AKI can lead to apoptosis and necrosis of renal cells, exacerbating the injury [5].

Mitochondrial dysfunction is another critical factor in AKI. It has been demonstrated that mitochondrial injury leads to impaired energy metabolism and increased production of reactive oxygen species (ROS), which can further damage renal cells. This mitochondrial dysfunction is often linked to the activation of cell death pathways, including apoptosis and necroptosis [41].

The transition from AKI to chronic kidney disease (CKD) is also influenced by maladaptive repair mechanisms following the initial injury. Inadequate repair of renal proximal tubular cells, often characterized by persistent inflammation and fibrosis, can lead to the development of CKD [9]. Studies have shown that oxidative stress and inflammatory signaling pathways, including the WNT/β-catenin pathway, play significant roles in this transition [42].

In terms of future directions in AKI research, a promising area is the development of biomarkers that can aid in the early detection and management of AKI. Current research is focused on identifying novel biomarkers that can indicate kidney injury before significant functional decline occurs. This is crucial, as early detection may facilitate timely interventions that could improve patient outcomes [10].

Advancements in understanding the molecular mechanisms of AKI also pave the way for therapeutic interventions targeting specific pathways involved in kidney injury and repair. For example, targeting oxidative stress, inflammatory pathways, and mitochondrial function may provide new avenues for treatment [36].

In conclusion, the mechanisms of AKI involve a complex interplay of hemodynamic, inflammatory, and cellular processes, with significant implications for patient outcomes. Continued research into these mechanisms and the development of biomarkers holds promise for improving the management and prognosis of AKI.

7 Conclusion ​

The mechanisms underlying acute kidney injury (AKI) are complex and multifaceted, involving a combination of hemodynamic changes, inflammatory responses, and nephrotoxicity. This review has highlighted the intricate interactions among pre-renal, intrinsic renal, and post-renal factors that contribute to the pathophysiology of AKI. Notably, hemodynamic alterations, such as reduced renal perfusion, play a critical role in the initiation of AKI, while inflammatory pathways exacerbate tubular injury and influence recovery. Oxidative stress and cellular death mechanisms, including apoptosis and necroptosis, further complicate the landscape of AKI. The identification of novel biomarkers for early detection of AKI represents a significant advancement in clinical practice, allowing for timely interventions that could mitigate kidney damage. Future research should focus on elucidating the underlying mechanisms of AKI, exploring potential therapeutic targets, and advancing biomarker development to enhance patient outcomes. As the understanding of AKI evolves, it is essential to integrate these insights into clinical strategies to prevent the progression of AKI to chronic kidney disease and improve overall renal health.

References ​

  • [1] David A Ferenbach;Joseph V Bonventre. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD.. Nature reviews. Nephrology(IF=39.8). 2015. PMID:25643664. DOI: 10.1038/nrneph.2015.3.
  • [2] Charlotte A Hoogstraten;Maaike M E Jacobs;Guido de Boer;Melissa A E van de Wal;Werner J H Koopman;Jan A M Smeitink;Frans G M Russel;Tom J J Schirris. Metabolic impact of genetic and chemical ADP/ATP carrier inhibition in renal proximal tubule epithelial cells.. Archives of toxicology(IF=6.9). 2023. PMID:37154957. DOI: 10.1007/s00204-023-03510-7.
  • [3] Marwa El Sabbahy;Vishal S Vaidya. Ischemic kidney injury and mechanisms of tissue repair.. Wiley interdisciplinary reviews. Systems biology and medicine(IF=7.9). 2011. PMID:21197658. DOI: 10.1002/wsbm.133.
  • [4] Chao Hu;Yue Sheng;Zhijian Qian. Current Understanding of Inflammatory Responses in Acute Kidney Injury.. Current gene therapy(IF=3.3). 2017. PMID:29446733. DOI: 10.2174/1566523218666180214092219.
  • [5] Yalda Rahbar Saadat;Seyed Mahdi Hosseiniyan Khatibi;Mohammadreza Ardalan;Abolfazl Barzegari;Sepideh Zununi Vahed. Molecular pathophysiology of acute kidney injury: The role of sirtuins and their interactions with other macromolecular players.. Journal of cellular physiology(IF=4.0). 2021. PMID:32989772. DOI: 10.1002/jcp.30084.
  • [6] Luis A Juncos;Patrick M Wieruszewski;Kianoush Kashani. Pathophysiology of Acute Kidney Injury in Critical Illness: A Narrative Review.. Comprehensive Physiology(IF=5.2). 2022. PMID:36073750. DOI: 10.1002/cphy.c210028.
  • [7] Hye Ryoun Jang;Hamid Rabb. Immune cells in experimental acute kidney injury.. Nature reviews. Nephrology(IF=39.8). 2015. PMID:25331787. DOI: 10.1038/nrneph.2014.180.
  • [8] Ewa Kwiatkowska;Sebastian Kwiatkowski;Violetta Dziedziejko;Izabela Tomasiewicz;Leszek Domański. Renal Microcirculation Injury as the Main Cause of Ischemic Acute Kidney Injury Development.. Biology(IF=3.5). 2023. PMID:36829602. DOI: 10.3390/biology12020327.
  • [9] Zhixiang Yu;Ying Zhou;Yuzhan Zhang;Xiaoxuan Ning;Tian Li;Lei Wei;Yingxue Wang;Xiao Bai;Shiren Sun. Cell Profiling of Acute Kidney Injury to Chronic Kidney Disease Reveals Novel Oxidative Stress Characteristics in the Failed Repair of Proximal Tubule Cells.. International journal of molecular sciences(IF=4.9). 2023. PMID:37511374. DOI: 10.3390/ijms241411617.
  • [10] Lianjiu Su;Jiahao Zhang;Zhiyong Peng. The role of kidney injury biomarkers in COVID-19.. Renal failure(IF=3.0). 2022. PMID:35930243. DOI: 10.1080/0886022X.2022.2107544.
  • [11] Merita Rroji;Marsida Kasa;Nereida Spahia;Saimir Kuci;Alfred Ibrahimi;Hektor Sula. Kidneys on the Frontline: Nephrologists Tackling the Wilds of Acute Kidney Injury in Trauma Patients-From Pathophysiology to Early Biomarkers.. Diagnostics (Basel, Switzerland)(IF=3.3). 2025. PMID:41095657. DOI: 10.3390/diagnostics15192438.
  • [12] Nikhilesh R Mazumder;Shilpa Junna;Pratima Sharma. The Diagnosis and Non-pharmacological Management of Acute Kidney Injury in Patients with Cirrhosis.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association(IF=12.0). 2023. PMID:37625862. DOI: 10.1016/j.cgh.2023.04.033.
  • [13] Xiao-Ming Meng;Li Wang;David J Nikolic-Paterson;Hui-Yao Lan. Innate immune cells in acute and chronic kidney disease.. Nature reviews. Nephrology(IF=39.8). 2025. PMID:40263532. DOI: 10.1038/s41581-025-00958-x.
  • [14] Tiziana Ciarambino;Pietro Crispino;Mauro Giordano. Gender and Renal Insufficiency: Opportunities for Their Therapeutic Management?. Cells(IF=5.2). 2022. PMID:36497080. DOI: 10.3390/cells11233820.
  • [15] Li Wan;Sean M Bagshaw;Christoph Langenberg;Takao Saotome;Clive May;Rinaldo Bellomo. Pathophysiology of septic acute kidney injury: what do we really know?. Critical care medicine(IF=6.0). 2008. PMID:18382194. DOI: 10.1097/CCM.0b013e318168ccd5.
  • [16] Seth D Glodowski;Gebhard Wagener. New insights into the mechanisms of acute kidney injury in the intensive care unit.. Journal of clinical anesthesia(IF=5.1). 2015. PMID:25480306. DOI: .
  • [17] Felipe Freitas;David Attwell. Pericyte-mediated constriction of renal capillaries evokes no-reflow and kidney injury following ischaemia.. eLife(IF=6.4). 2022. PMID:35285797. DOI: .
  • [18] Wilfred Druml. Systemic consequences of acute kidney injury.. Current opinion in critical care(IF=3.4). 2014. PMID:25259720. DOI: 10.1097/MCC.0000000000000150.
  • [19] Francesco Guzzi;Luigi Cirillo;Rosa Maria Roperto;Paola Romagnani;Elena Lazzeri. Molecular Mechanisms of the Acute Kidney Injury to Chronic Kidney Disease Transition: An Updated View.. International journal of molecular sciences(IF=4.9). 2019. PMID:31590461. DOI: 10.3390/ijms20194941.
  • [20] Andrea Havasi;Steven C Borkan. Apoptosis and acute kidney injury.. Kidney international(IF=12.6). 2011. PMID:21562469. DOI: 10.1038/ki.2011.120.
  • [21] Benedikt Kolbrink;Friedrich A von Samson-Himmelstjerna;James M Murphy;Stefan Krautwald. Role of necroptosis in kidney health and disease.. Nature reviews. Nephrology(IF=39.8). 2023. PMID:36596919. DOI: 10.1038/s41581-022-00658-w.
  • [22] Qi Feng;Xiaoyue Yu;Yingjin Qiao;Shaokang Pan;Rui Wang;Bin Zheng;Hui Wang;Kai-Di Ren;Hui Liu;Yang Yang. Ferroptosis and Acute Kidney Injury (AKI): Molecular Mechanisms and Therapeutic Potentials.. Frontiers in pharmacology(IF=4.8). 2022. PMID:35517803. DOI: 10.3389/fphar.2022.858676.
  • [23] Brian B Ratliff;Wasan Abdulmahdi;Rahul Pawar;Michael S Wolin. Oxidant Mechanisms in Renal Injury and Disease.. Antioxidants & redox signaling(IF=6.1). 2016. PMID:26906267. DOI: 10.1089/ars.2016.6665.
  • [24] Hsin-Jung Ho;Hitoshi Shirakawa. Oxidative Stress and Mitochondrial Dysfunction in Chronic Kidney Disease.. Cells(IF=5.2). 2022. PMID:36611880. DOI: 10.3390/cells12010088.
  • [25] Masahiro Nezu;Tomokazu Souma;Lei Yu;Takafumi Suzuki;Daisuke Saigusa;Sadayoshi Ito;Norio Suzuki;Masayuki Yamamoto. Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression.. Kidney international(IF=12.6). 2017. PMID:27789056. DOI: 10.1016/j.kint.2016.08.023.
  • [26] Keiko Hosohata. Role of Oxidative Stress in Drug-Induced Kidney Injury.. International journal of molecular sciences(IF=4.9). 2016. PMID:27809280. DOI: .
  • [27] Angara Sureshbabu;Stefan W Ryter;Mary E Choi. Oxidative stress and autophagy: crucial modulators of kidney injury.. Redox biology(IF=11.9). 2015. PMID:25613291. DOI: .
  • [28] Hina Rashid;Abdulmajeed Jali;Mohammad Suhail Akhter;Sayed Aliul Hasan Abdi. Molecular Mechanisms of Oxidative Stress in Acute Kidney Injury: Targeting the Loci by Resveratrol.. International journal of molecular sciences(IF=4.9). 2023. PMID:38203174. DOI: 10.3390/ijms25010003.
  • [29] Jian Wu;Haojie Shang;An Zhang;Yu He;Yonghua Tong;Qiu Huang;Xiao Liu;Zhiqiang Chen;Kun Tang. Antioxidant nanozymes in kidney injury: mechanism and application.. Nanoscale(IF=5.1). 2023. PMID:37547960. DOI: 10.1039/d3nr01954c.
  • [30] Shrikant R Mulay;Alexander Holderied;Santhosh V Kumar;Hans-Joachim Anders. Targeting Inflammation in So-Called Acute Kidney Injury.. Seminars in nephrology(IF=3.5). 2016. PMID:27085732. DOI: .
  • [31] Sanjeev Noel;Radhika Kapoor;Hamid Rabb. New approaches to acute kidney injury.. Clinical kidney journal(IF=4.6). 2024. PMID:39583139. DOI: 10.1093/ckj/sfae265.
  • [32] Sean M Bagshaw;Rinaldo Bellomo. Early diagnosis of acute kidney injury.. Current opinion in critical care(IF=3.4). 2007. PMID:17975383. DOI: 10.1097/MCC.0b013e3282f07570.
  • [33] Nicole Nourie;Rita Ghaleb;Carmen Lefaucheur;Kevin Louis. Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury.. Biomolecules(IF=4.8). 2024. PMID:38254682. DOI: 10.3390/biom14010082.
  • [34] Marlies Ostermann;Matthieu Legrand;Melanie Meersch;Nattachai Srisawat;Alexander Zarbock;John A Kellum. Biomarkers in acute kidney injury.. Annals of intensive care(IF=5.5). 2024. PMID:39279017. DOI: 10.1186/s13613-024-01360-9.
  • [35] Chenchen Zou;Chentong Wang;Lin Lu. Advances in the study of subclinical AKI biomarkers.. Frontiers in physiology(IF=3.4). 2022. PMID:36091391. DOI: 10.3389/fphys.2022.960059.
  • [36] Ya-Long Feng;Yang Yang;Hua Chen. Small molecules as a source for acute kidney injury therapy.. Pharmacology & therapeutics(IF=12.5). 2022. PMID:35306111. DOI: 10.1016/j.pharmthera.2022.108169.
  • [37] Fumiaki Tanemoto;Imari Mimura. Therapies Targeting Epigenetic Alterations in Acute Kidney Injury-to-Chronic Kidney Disease Transition.. Pharmaceuticals (Basel, Switzerland)(IF=4.8). 2022. PMID:35215236. DOI: 10.3390/ph15020123.
  • [38] Ning Li;Lu Han;Xinyue Wang;Ou Qiao;Li Zhang;Yanhua Gong. Biotherapy of experimental acute kidney injury: emerging novel therapeutic strategies.. Translational research : the journal of laboratory and clinical medicine(IF=5.9). 2023. PMID:37329950. DOI: 10.1016/j.trsl.2023.06.002.
  • [39] Kambiz Kalantari;Mitchell H Rosner. Recent advances in the pharmacological management of sepsis-associated acute kidney injury.. Expert review of clinical pharmacology(IF=3.0). 2021. PMID:34493146. DOI: 10.1080/17512433.2021.1978287.
  • [40] Dongfang Lv;Huihui Jiang;Xianzhen Yang;Yi Li;Weipin Niu;Denglu Zhang. Advances in understanding of dendritic cell in the pathogenesis of acute kidney injury.. Frontiers in immunology(IF=5.9). 2024. PMID:38433836. DOI: 10.3389/fimmu.2024.1294807.
  • [41] Mark Hepokoski;Prabhleen Singh. Mitochondria as mediators of systemic inflammation and organ cross talk in acute kidney injury.. American journal of physiology. Renal physiology(IF=3.4). 2022. PMID:35379000. DOI: 10.1152/ajprenal.00372.2021.
  • [42] Jinxiu Hu;Jiao Qiao;Qun Yu;Bing Liu;Junhui Zhen;Yue Liu;Qiqi Ma;Yanmei Li;Qianhui Wang;Cheng Wang;Zhimei Lv. Role of SIK1 in the transition of acute kidney injury into chronic kidney disease.. Journal of translational medicine(IF=7.5). 2021. PMID:33588892. DOI: 10.1186/s12967-021-02717-5.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Acute Kidney Injury · Pathophysiological Mechanisms · Biomarkers

© 2025 MaltSci